Stock CALADRIUS BIOSCIENCES INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Caladrius Biosciences Inc Nasdaq

Equities

US1280581042

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Caladrius Biosciences Inc
Apr. 23 Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer MT
Apr. 23 Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
GL
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
AQ
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference
GL
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
AQ
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
GL
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
GL
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
AQ
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
GL
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Lisata Therapeutics to Present at NobleCon19 Investor Conference
GL
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
GL
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. Stock
  5. News Caladrius Biosciences Inc
  6. Press Releases